Equities Analysts Set Expectations for AVDL FY2025 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Avadel Pharmaceuticals in a note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of $0.95 for the year, down from their prior estimate of $1.05. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.50) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2026 earnings at $2.00 EPS and FY2028 earnings at $3.15 EPS.

Other analysts have also issued research reports about the stock. HC Wainwright dropped their price target on shares of Avadel Pharmaceuticals from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Avadel Pharmaceuticals in a research report on Tuesday. Finally, Oppenheimer lifted their price target on Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $24.43.

Avadel Pharmaceuticals Price Performance

Shares of NASDAQ AVDL opened at $10.91 on Thursday. The firm’s 50 day simple moving average is $13.49 and its 200-day simple moving average is $15.02. Avadel Pharmaceuticals has a 12 month low of $10.39 and a 12 month high of $19.09. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -13.81 and a beta of 1.47.

Avadel Pharmaceuticals (NASDAQ:AVDL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.03. Avadel Pharmaceuticals had a negative return on equity of 93.34% and a negative net margin of 52.53%. The firm had revenue of $50.00 million for the quarter, compared to analyst estimates of $48.43 million. During the same period last year, the company earned ($0.41) earnings per share. Avadel Pharmaceuticals’s revenue for the quarter was up 624.6% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AVDL. BNP Paribas Financial Markets increased its stake in Avadel Pharmaceuticals by 60.5% during the 1st quarter. BNP Paribas Financial Markets now owns 4,469 shares of the company’s stock worth $75,000 after buying an additional 1,685 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Avadel Pharmaceuticals during the first quarter worth approximately $353,000. Russell Investments Group Ltd. purchased a new stake in shares of Avadel Pharmaceuticals during the first quarter worth approximately $1,943,000. Avantax Advisory Services Inc. raised its stake in Avadel Pharmaceuticals by 123.9% in the 1st quarter. Avantax Advisory Services Inc. now owns 55,756 shares of the company’s stock valued at $942,000 after purchasing an additional 30,856 shares during the last quarter. Finally, Lord Abbett & CO. LLC purchased a new position in Avadel Pharmaceuticals in the 1st quarter valued at $3,264,000. Institutional investors and hedge funds own 69.19% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.